Alytas Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 2

Alytas Therapeutics General Information

Description

Operator of a biotechnology company intended to develop immunological therapy concepts for the treatment of pathological obesity. The company specializes in the development and commercialization of antibodies in the field of senescence, related degenerative processes, and pathologies for different forms of therapy for obesity with an acceptable side-effect profile and improved efficacy, enabling the medical industry with non-surgical, effective, and sustainable therapeutic options against the worldwide epidemic increase in obesity.

Contact Information

Website
www.alytas.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Hans-Knöll-Strasse 6
  • 07745 Jena
  • Germany
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Vertical(s)
Life Sciences
Corporate Office
  • Hans-Knöll-Strasse 6
  • 07745 Jena
  • Germany

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alytas Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC Completed Generating Revenue
To view Alytas Therapeutics’s complete valuation and funding history, request access »

Alytas Therapeutics Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 4

    Pending

  • Expiring in next 12 mo

Alytas Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020223507-A1 Means for specifically eliminating perilipin-1 fragment presenting adipocytes Pending 13-Feb-2019
EP-3908373-A1 Means for specifically eliminating perilipin-1 fragment presenting adipocytes Pending 13-Feb-2019
US-20220153822-A1 Means for specifically eliminating perilipin-1 fragment presenting adipocytes Pending 13-Feb-2019
EP-3695883-A1 Means for specifically eliminating perilipin-1 fragment presenting adipocytes Inactive 13-Feb-2019
CA-3129639-A1 Means for specifically eliminating perilipin-1 fragment presenting adipocytes Pending 13-Feb-2019 C07K16/18
To view Alytas Therapeutics’s complete patent history, request access »

Alytas Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Xlife Sciences Venture Capital Minority
To view Alytas Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Alytas Therapeutics FAQs

  • When was Alytas Therapeutics founded?

    Alytas Therapeutics was founded in 2018.

  • Where is Alytas Therapeutics headquartered?

    Alytas Therapeutics is headquartered in Jena, Germany.

  • What industry is Alytas Therapeutics in?

    Alytas Therapeutics’s primary industry is Biotechnology.

  • Is Alytas Therapeutics a private or public company?

    Alytas Therapeutics is a Private company.

  • What is Alytas Therapeutics’s current revenue?

    The current revenue for Alytas Therapeutics is .

  • Who are Alytas Therapeutics’s investors?

    and Xlife Sciences have invested in Alytas Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »